Research has shown that anti VEGF drugs relax blood vessels by releasing nitric oxide, and ranibizumab can reduce neovascularization in the optic disc and eliminate macular edema, thereby reducing intraocular pressure in patients. The gene discussed is VEGFA; the disease is macular retinal edema.